Cagrilintide + Semaglutide

Cagrilintide + Semaglutide is a dual-hormone therapeutic combination designed to target complementary pathways involved in appetite regulation and metabolic control. Cagrilintide is a long-acting amylin analog that activates amylin and calcitonin receptors, influencing satiety signaling, gastric emptying, and energy intake. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion and reduces appetite through central and peripheral mechanisms.